Embecta is global medical device company focused on providing solutions to improve the health and wellbeing of people living with diabetes. Co. has a portfolio of marketed products, including various of pen needles, syringes and safety devices, which are complemented by its proprietary digital applications. Co.'s pen needles are sterile, single-use, medical devices, designed to be used in conjunction with insulin pens and are used to inject insulin or other diabetes medications. Co. also sells safety pen needles, which include resin injection-molded shields on both ends of the cannula that automatically deploy to help prevent needlestick exposure and injury during injection and disposal. More details about Embecta at:
http://www.embecta.com.
ETFs holding EMBC »
Should Embecta shares be counted among the
Top 10 Cheap Healthcare Stocks? To start, we see that the recent trading price for EMBC stock is $10.15 (as of 5/3/2024). The most recent quarter's (MRQ) earnings result, annualized, was $2.44/share. Looking at the sum total of quarterly earnings across the trailing twelve month (TTM) period, Embecta produced $1.89/share. And taking the median quarterly result across the TTM period, and annualizing it, results in $2.4/share. Comparing these various earnings metrics against the stock price, we end up with a PE ratio of 4.2 for the TTM Median method, 4.2 for price to earnings using MRQ annualized, and 5.4 for current price/TTM earnings. Based on EMBC's history, that recent TTM PE is low relative to the historical average, with the recent PE 40.0% lower than the average (TTM method) of 9.0.